----0 - getGroupsByUser
Array ( [0] => stdClass Object ( [title] => Public ) )
----0 - getAuthorisedViewLevels
Array ( [0] => 1 [1] => 1 )
----0 - groups
Array ( [0] => 1 )

Translate page

-- Virtual Education Program: 2015 Edition 

 

Presentations from a CML Opinion Leader Meeting

We are pleased to make available a new series of presentations from the COLT Meeting 2014, an annual CML Opinion Leader Training that took place in Adelaide (Australia). Modules currently featured include; high risk CML, optimizing therapy, front line therapy in CML chronic phase and new developments in CML - all presented by leaders in the field. 

David RossAgnes YONG w labcoat1

Dr David Ross            Dr Agnes Yong

 

Session 4: New developments in CML

  • Is CML a curable disease? 
    (Dr David Ross)
  • Transplant and immunotherapy in CML
    (Dr Agnes Yong)

 

Deborah White                                                                

 

 

 

Biomarkers and response monitoring beyond PCR?
Deborah White - SAHMRI, University of Adelaide

  • Predictive biomarkers
  • Cytokines, growth factors and chemokines: TGF and IL6
  • KIR2DS1 genotype and inferior cytogenetic response: SPIRIT1
  • CIP2A and response
  • Imatinib drug levels and compliance
     

 

                    

 

Collage COLT Session3

     A/Prof. Branford       Prof. Hughes

                

 

 

 

Session 3: High risk CML

  • Mechanisms of resistance to TKI therapy 
    (A/Prof. Susan Branford)
  • When frontline TKI therapy fails
    (Prof. Timothy Hughes)

 

 

Jorge Cortes 2013                     Prof. Jorge Cortes                             

 

 

    Session 2: Optimizing Therapy in CML

  • Evolution of frontline therapy in CML
  • Treatment outcomes for different time periods
  • Factors predicting optimal response
  • Treatment choices in CML including 2nd/3rd generation of TKI's
  • Risks and outcomes after treatment discontinuation 

 

 We are very grateful for the support of Brandcast media to produce this web stream
VEP Müller

 

 

  

        

 

 

Molecular monitoring in CML - getting to a safe place
Martin C. Müller, Institute for Hematology and Oncology (IHO) and Medical Faculty Mannheim, University of Heidelberg, Germany 

  • What do we consider safe?
  • Cytogenetic and molecular monitoring: European LeukemiaNet recommendations
  • Molecular monitoring every 3 months - enough for all patients?
  • Achieving deep remissions
  • Definitions of molecular response
  • Compliance check
  • Conclusions

 

Collage COLT module 2         Prof. Melo             Prof. Hughes     A/Prof. Branford

                    

Session 1: Front line Therapy of CML-CP

  • Addressing key biological questions in CML 
    (Prof. Junia Melo)
  • Risk profiles, molecular targets, pharmacokinetics 
    (Prof. Timothy Hughes)
  • The importance of deep molecular response in CML patients 
    (A/Prof. Susan Branford)